Other recent trials examining cardiovascular and kidney outcomes for novel glucose-lowering agents for diabetes other than SGLT2 inhibitors, while including a broad range of participants, also do not routinely attempt to stratify participants for baseline variables of pre-existing treatment intensity or disease duration [28–30]. This evidence concerns the gene SLC5A2 and diabetes mellitus.